Drugs / WRAIR-PAM-CF1
WRAIR-PAM-CF1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05453578 Comparator | Oct 2022 → Apr 2025 | bacterial infectious disease, cystic fibrosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WRAIR-PAM-CF1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05453578 ↗ |
| Known as | Walter Reed Army Institute of Research- PAM-Cystic Fibrosis1 | “bacteriophage product Walter Reed Army Institute of Research- PAM-Cystic Fibrosis1 (WRAIR-PAM-CF1), directed at Pseudomonas aeruginosa” NCT05453578 ↗ |
| Action | Inhibit | “This trial will investigate the activity of phages in reducing P. aeruginosa colony counts” PMID 36578069 ↗ Dec 2022 |
| Modality | Other / unclassified | “4 component anti-pseudomonal bacteriophage mixture” NCT05453578 ↗ |
| Route | Intravenous | “administered intravenously” NCT05453578 ↗ |